Pathway-Centric Integrative Analysis Identifies RRM2 as a Prognostic Marker in Breast Cancer Associated with Poor Survival and Tamoxifen Resistance123

[1]  T. Lumley,et al.  gplots: Various R Programming Tools for Plotting Data , 2015 .

[2]  Sarmistha Nanda,et al.  Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance , 2014, Breast Cancer Research and Treatment.

[3]  S. Fuqua,et al.  Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight , 2014, Breast Cancer Research and Treatment.

[4]  Yongguo Yu,et al.  Clinical and molecular genetic study of infantile-onset Pompe disease in Chinese patients: identification of 6 novel mutations. , 2014, Gene.

[5]  Sarah J. Kurley,et al.  MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. , 2014, The Journal of clinical investigation.

[6]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[7]  David A. Peterson,et al.  AKT-Induced Tamoxifen Resistance Is Overturned by RRM2 Inhibition , 2013, Molecular Cancer Research.

[8]  R. Schiff,et al.  Cancer Cells Resistant to Therapy Promote Cell Surface Relocalization of GRP78 Which Complexes with PI3K and Enhances PI(3,4,5)P3 Production , 2013, PloS one.

[9]  Javed Siddiqui,et al.  Activating ESR1 mutations in hormone-resistant metastatic breast cancer , 2013, Nature Genetics.

[10]  C. Creighton,et al.  Acceleration of the Glycolytic Flux by Steroid Receptor Coactivator-2 Is Essential for Endometrial Decidualization , 2013, PLoS genetics.

[11]  Benjamin G. Bitler,et al.  Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. , 2013, Cell reports.

[12]  Chad J Creighton,et al.  The molecular profile of luminal B breast cancer , 2012, Biologics : targets & therapy.

[13]  G. Marcucci,et al.  RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. , 2012, Blood.

[14]  Ji Luo,et al.  A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis , 2012, Science.

[15]  M. Imieliński,et al.  Integrated Proteomic, Transcriptomic, and Biological Network Analysis of Breast Carcinoma Reveals Molecular Features of Tumorigenesis and Clinical Relapse* , 2012, Molecular & Cellular Proteomics.

[16]  Yair Lotan,et al.  Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. , 2011, Cancer research.

[17]  David Haussler,et al.  Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling , 2011, Proceedings of the National Academy of Sciences.

[18]  Gregory Stephanopoulos,et al.  Amplification of phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis , 2012, BMC Proceedings.

[19]  A. Shojaie,et al.  Metabolomic Profiling Reveals a Role for Androgen in Activating Amino Acid Metabolism and Methylation in Prostate Cancer Cells , 2011, PloS one.

[20]  J. Olson,et al.  Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Morris,et al.  Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Hyungwon Choi,et al.  Metabolites of Purine Nucleoside Phosphorylase (NP) in Serum Have the Potential to Delineate Pancreatic Adenocarcinoma , 2011, PloS one.

[23]  V. Cryns,et al.  Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. , 2011, Molecular endocrinology.

[24]  이연수.  Functional genomics reveal that the serine synthesis pathway is essential in breast cancer , 2011 .

[25]  H. An,et al.  Proteomic molecular portrait of interface zone in breast cancer. , 2010, Journal of proteome research.

[26]  M. Imieliński,et al.  In Situ Proteomic Analysis of Human Breast Cancer Epithelial Cells Using Laser Capture Microdissection: Annotation by Protein Set Enrichment Analysis and Gene Ontology* , 2010, Molecular & Cellular Proteomics.

[27]  S. Schnitt,et al.  Mapping the cellular and molecular heterogeneity of normal and malignant breast tissues and cultured cell lines , 2010, Breast Cancer Research.

[28]  Kounosuke Watabe,et al.  Metabolic genes in cancer: their roles in tumor progression and clinical implications. , 2010, Biochimica et biophysica acta.

[29]  Detlev Suckau,et al.  Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. , 2010, Journal of proteome research.

[30]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[31]  R. Saxton,et al.  Tumor proteomic profiling predicts the susceptibility of breast cancer to chemotherapy. , 2009, International journal of oncology.

[32]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[33]  J. Ross,et al.  MammaPrint™ 70-gene signature: another milestone in personalized medical care for breast cancer patients , 2009, Expert review of molecular diagnostics.

[34]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[35]  John T. Wei,et al.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.

[36]  Michael Q. Zhang,et al.  Gene set-based module discovery in the breast cancer transcriptome , 2009, BMC Bioinformatics.

[37]  Jian Li,et al.  Omics-based Profiling of Carcinoma of the Breast and Matched Regional Lymph Node Metastasis , 2022 .

[38]  Jiang Shou,et al.  Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. , 2008, Cancer research.

[39]  D. Raftery,et al.  Metabolomics-based methods for early disease diagnostics , 2008, Expert review of molecular diagnostics.

[40]  A. Rosenberg,et al.  Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 down-regulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy , 2008, Cancer biology & therapy.

[41]  Gianluca Bontempi,et al.  Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen , 2008, BMC Genomics.

[42]  Somnath Datta,et al.  Classification of Breast Cancer versus Normal Samples from Mass Spectrometry Profiles Using Linear Discriminant Analysis of Important Features Selected by Random Forest , 2008, Statistical applications in genetics and molecular biology.

[43]  R. Schiff,et al.  Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. , 2008, Cancer research.

[44]  C. Perou,et al.  Molecular Subtypes in Breast Cancer Evaluation and Management: Divide and Conquer , 2008, Cancer investigation.

[45]  M. Wong,et al.  Differential regulation of cyclic AMP synthesis by estrogen in MCF7 cells. , 2007, Biochemical and biophysical research communications.

[46]  C. Laronga,et al.  Proteomic approach to breast cancer. , 2007, Cancer control : journal of the Moffitt Cancer Center.

[47]  I. Bertini,et al.  Metabolomics: available results, current research projects in breast cancer, and future applications. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  J. Bergh,et al.  Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Lisa A Carey,et al.  Gene-expression analysis and the basal-like breast cancer subtype. , 2007, Future oncology.

[50]  Chen Yang,et al.  Comparative Metabolomics of Breast Cancer , 2006, Pacific Symposium on Biocomputing.

[51]  T. Bathen,et al.  MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status , 2007, Breast Cancer Research and Treatment.

[52]  A. Giuliano,et al.  Proteomic profiling of primary breast cancer predicts axillary lymph node metastasis. , 2006, Cancer research.

[53]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[54]  R. Tibshirani,et al.  On testing the significance of sets of genes , 2006, math/0610667.

[55]  G. M. Nagaraja,et al.  Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics , 2006, Oncogene.

[56]  T. Bathen,et al.  Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters , 2006, NMR in biomedicine.

[57]  F. Monzon.  A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer , 2006 .

[58]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[59]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[60]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[61]  M. Hirai,et al.  Integration of transcriptomics and metabolomics for understanding of global responses to nutritional stresses in Arabidopsis thaliana. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[62]  E. Petricoin,et al.  Genomic and proteomic approaches for studying human cancer: Prospects for true patient-tailored therapy , 2004, Human Genomics.

[63]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[64]  B. Sitter,et al.  High‐resolution magic angle spinning MRS of breast cancer tissue , 2002, NMR in biomedicine.

[65]  David Miles,et al.  Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  H. Preisler,et al.  Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[67]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[68]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[69]  Barbara L. Smith,et al.  Evaluating human breast ductal carcinomas with high-resolution magic-angle spinning proton magnetic resonance spectroscopy. , 1998, Journal of magnetic resonance.

[70]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[71]  H. Frierson,et al.  Pathologic Findings in Nonpalpable Invasive Breast Cancer , 1992, The American journal of surgical pathology.

[72]  C. Carter,et al.  Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989, Cancer.

[73]  Donald E. Henson,et al.  Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989 .